Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Gains from Investment Securities (2023 - 2024)

Sagimet Biosciences (SGMT) has 2 years of Gains from Investment Securities data on record, last reported at $49000.0 in Q3 2024.

  • For Q3 2024, Gains from Investment Securities rose 9739.36% year-over-year to $49000.0; the TTM value through Dec 2024 reached -$55000.0, changed N/A, while the annual FY2025 figure was $152000.0, 2.01% up from the prior year.
  • Gains from Investment Securities reached $49000.0 in Q3 2024 per SGMT's latest filing, down from $3.5 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $3.5 million in Q1 2024 and bottomed at -$104000.0 in Q4 2023.